Novo Nordisk A/S (NYSE:NVO) Shares Purchased by Herold Advisors Inc.

Herold Advisors Inc. raised its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 108.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 5,000 shares of the company’s stock after purchasing an additional 2,600 shares during the period. Herold Advisors Inc.’s holdings in Novo Nordisk A/S were worth $517,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in NVO. Hartford Investment Management Co. increased its position in shares of Novo Nordisk A/S by 63.8% in the third quarter. Hartford Investment Management Co. now owns 3,924 shares of the company’s stock worth $357,000 after acquiring an additional 1,528 shares in the last quarter. Capital Investment Advisors LLC acquired a new stake in shares of Novo Nordisk A/S in the third quarter worth $222,000. Newbridge Financial Services Group Inc. increased its position in shares of Novo Nordisk A/S by 69.1% in the third quarter. Newbridge Financial Services Group Inc. now owns 487 shares of the company’s stock worth $44,000 after acquiring an additional 199 shares in the last quarter. GHP Investment Advisors Inc. grew its holdings in Novo Nordisk A/S by 100.0% during the 3rd quarter. GHP Investment Advisors Inc. now owns 4,560 shares of the company’s stock valued at $415,000 after purchasing an additional 2,280 shares in the last quarter. Finally, Boston Trust Walden Corp grew its holdings in Novo Nordisk A/S by 100.0% during the 3rd quarter. Boston Trust Walden Corp now owns 19,346 shares of the company’s stock valued at $1,759,000 after purchasing an additional 9,673 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Up 0.9 %

NYSE NVO traded up $1.07 during trading hours on Friday, reaching $126.86. 3,310,701 shares of the company traded hands, compared to its average volume of 4,797,428. Novo Nordisk A/S has a 12 month low of $75.56 and a 12 month high of $138.28. The company has a current ratio of 0.82, a quick ratio of 0.64 and a debt-to-equity ratio of 0.19. The stock has a market capitalization of $569.29 billion, a PE ratio of 46.99, a PEG ratio of 2.11 and a beta of 0.41. The company has a 50 day moving average of $126.86 and a two-hundred day moving average of $111.98.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Wednesday, January 31st. The company reported $0.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.66 by $0.05. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. The company had revenue of $9.51 billion for the quarter, compared to the consensus estimate of $9.14 billion. As a group, equities analysts expect that Novo Nordisk A/S will post 3.32 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently declared a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Stockholders of record on Monday, March 25th were given a $0.664 dividend. This is an increase from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. This represents a dividend yield of 0.9%. The ex-dividend date was Friday, March 22nd. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 48.89%.

Analysts Set New Price Targets

A number of research firms recently weighed in on NVO. BMO Capital Markets began coverage on shares of Novo Nordisk A/S in a report on Friday, April 12th. They set an “outperform” rating and a $163.00 price target for the company. Morgan Stanley began coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 price target for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a report on Thursday, April 18th. Finally, UBS Group began coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 16th. They set a “neutral” rating for the company. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $133.60.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.